The firm will make its artificial intelligence-based Lunit SCOPE IO platform available to SITC member researchers.

Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) ...

Native Americans face the longest travel times, even after accounting for distances in rural areas, according to results of a ...

Researchers reveal that gut microbiota influence the effectiveness of immune checkpoint inhibitors (ICIs) in cancer treatment ...

Next step is “secret shopper” research to identify unnecessary barriers in medical supply system for cancer patients.

AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Produc ...

(IN BRIEF) AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for approval as a ...

Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer ...

Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which ...

(Alliance News) - AstraZeneca PLC on Monday said Imfinzi has been recommended for approval in the EU as monotherapy for limited-stage small cell lung cancer.

AstraZeneca (AZN.L, AZN) announced Imfinzi was recommended for approval in the European Union by CHMP as first and only immunotherapy ...

Stuart Beaton, who was diagnosed with lung cancer, says in a lawsuit that he was forced to work in a building contaminated with asbestos ...